Clinical Trials on Metastatic Cutaneous Melanoma

Total 12772 results

Bristol-Myers Squibb

Completed

Long-term Data Collection for Subjects in MDX-010 Studies (MDX010-28)

Metastatic Melanoma

United States
Yousef Zakharia
University of Iowa; Exelixis

Recruiting

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Advanced Metastatic Melanoma

United States
Columbia University
Merck Sharp & Dohme LLC

Terminated

MRI and PET to Assess Pembrolizumab Response (MPAK)

Malignant Melanoma, Metastatic

United States
Wilson Miller

Active, not recruiting

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

Metastatic Malignant Melanoma

Canada
Lynn E. Spitler, MD
University of California, San Francisco

Completed

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI)

Malignant Melanoma, Metastatic

United States
Northern California Melanoma Center
Pfizer; Schering-Plough

Terminated

Temodar and Sutent as Therapy for Melanoma

Metastatic Malignant Melanoma

United States
Provectus Biopharmaceuticals, Inc.

Active, not recruiting

A Study to Assess PV-10 Chemoablation of Cancer of the Liver

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Uveal Melanoma | Metastatic Pancreatic Cancer | Metastatic Colon Cancer | Metastatic Ocular Melanoma | Cancer Metastatic to the Liver

United States
Italian Network for Tumor Biotherapy
Bristol-Myers Squibb

Completed

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (NIBIT-M1)

Metastatic Malignant Melanoma

Italy
NYU Langone Health

Completed

Inducing Systemic Immunity and Regressions in Metastatic Melanoma

Metastatic Malignant Melanoma
MedImmune LLC

Completed

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Melanoma | Malignant Metastatic Melanoma

United States
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States
National Cancer Institute (NCI)

Terminated

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cancer

United States
National Cancer Institute (NCI)

Terminated

MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes

Metastatic Cancer | Metastatic Melanoma | Metastatic Renal Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | Clinical... and other conditions

United States
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
DNA Therapeutics

Completed

DNA Repair Inhibitor & Irradiation on Melanoma (DRIIM)

Local Metastatic Melanoma

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the Liver

United States
Biocad

Active, not recruiting

Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma (FLAT)

Unresectable or Metastatic Melanoma

Russian Federation
Ludwig Institute for Cancer Research
Cancer Research Institute, NY, USA

Terminated

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Unresectable or Metastatic Melanoma

United States, Australia
Bristol-Myers Squibb

Completed

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Unresectable or Metastatic Melanoma

United States, Germany, Italy, United Kingdom, Canada, Denmark, Netherlands, Spain, Belgium, France, Switzerland, Israel, Austria, Brazil
Bristol-Myers Squibb

Completed

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Advanced or Metastatic Melanoma

United States
University of California, San Francisco
Novartis

Completed

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

BRAF Mutant Metastatic Melanoma

United States
Centre Hospitalier Universitaire de Nice

Completed

Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy (AMMAM)

Metastatic (Stage IV) Melanoma

France
Vastra Gotaland Region

Withdrawn

Surgery of Melanoma Metastases After Systemic Therapy (SUMMIST)

Melanoma | Surgery | Metastatic Melanoma | Melanoma Stage IV

Sweden
Delcath Systems Inc.
National Cancer Institute (NCI)

Completed

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Metastatic Cancer | Intraocular Melanoma | Melanoma (Skin)

United States
Haukeland University Hospital
Norwegian Cancer Society; The Norwegian Melanoma Group

Terminated

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Metastatic Malignant Melanoma | Unresectable Malignant Melanoma

Norway
Polaris Group

Completed

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors

Taiwan, United States
Memorial Sloan Kettering Cancer Center
Iovance Biotherapeutics, Inc.

Recruiting

Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma

Melanoma | Metastatic Melanoma | Metastatic Uveal Melanoma | Uveal Melanoma

United States
Novartis Pharmaceuticals

Completed

Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma

BRAF-positive Metastatic Melanoma

United States
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma

United States, France, Poland, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, Russian Federation
Philogen S.p.A.

Active, not recruiting

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Metastatic Melanoma Stage IV

Italy, Germany
St. Louis University

Completed

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NeoPembroMel)

Melanoma | Metastatic Melanoma | Stage IV Melanoma | Unresectable Malignant Neoplasm | Stage III Melanoma

United States
Castle Biosciences Incorporated

Terminated

Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes (EXPAND)

Cutaneous Melanoma

United States
Mayo Clinic

Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Malignant Solid Neoplasm | Renal Cell Carcinoma | Hepatocellular Carcinoma | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Lung Non-Small Cell Carcinoma | Urothelial Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

Liver Metastases | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Extraocular Extension Melanoma

United States
Perspective Therapeutics

Recruiting

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

Metastatic Melanoma | Melanoma (Skin) | Mucosal Melanoma | Melanoma Stage IV | Melanoma Stage III | Melanoma, Uveal

United States
Daiichi Sankyo, Inc.
Plexxikon

Terminated

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

V600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF Inhibitor

United States, Germany, France
Millennium Pharmaceuticals, Inc.

Completed

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Melanoma | Solid Tumor | Metastatic Melanoma | Neoplasm

United States, United Kingdom
Samsung Medical Center

Completed

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations

Metastatic Melanoma With KIT Aberration

Korea, Republic of
Case Comprehensive Cancer Center

Completed

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Metastatic or Unresectable Melanoma

United States
Centre Hospitalier Universitaire de Nice

Recruiting

Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma (BMUMM)

Cutaneous Melanoma

France
The Methodist Hospital Research Institute
Genentech, Inc.

Recruiting

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Cutaneous Melanoma

United States
University of Louisville

Recruiting

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Cutaneous Melanoma

United States
Ruhr University of Bochum

Completed

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

Cutaneous Malignant Melanoma

Germany
Pfizer
Pierre Fabre Laboratories

Active, not recruiting

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Melanoma

United States, Spain, Belgium, Canada, Netherlands
University of Southern California
National Cancer Institute (NCI)

Terminated

Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma

Melanoma | Cutaneous Melanoma

United States
University of Utah
Verastem, Inc.

Recruiting

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE)

Melanoma

United States
Institut Paoli-Calmettes
Société Francophone d'Onco-Gériatrie

Unknown

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies (EPITOP-01)

Advanced or Metastatic NSCLC | Advanced or Metastatic Melanoma

France
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma

Unresectable, Recurrent or Metastatic Melanoma | Untreated Mucosal or Acral Lentiginous Melanoma

China

Clinical Trials on Metastatic Cutaneous Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations